|
1.
|
|
10 p, 1.2 MB |
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
/
Argilés Martínez, Guillem ;
Mulet, N. (Memorial Sloan Kettering Cancer Center) ;
Valladares-Ayerbes, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Viéitez, J.M. (Hospital Universitario Central de Asturias) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
García-Alfonso, P. (H. Gregorio Marañón) ;
Santos, C. (ICO. H. Duran i Reynals) ;
Tobeña, M. (Institut d'Investigació Biomèdica Sant Pau) ;
García Paredes, B. (H. Universitario Clínico San Carlos) ;
Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cano, M.T. (H. Universitario Reina Sofía) ;
Loupakis, F. (IOV (Istituto oncologico Veneto)) ;
Rodríguez-Garrote, M. (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ;
Rivera, F. (Instituto de Investigación Marqués de Valdecilla) ;
Goldberg, R.M. (West Virgina University Cancer Institute) ;
Cremolini, Chiara (A. O. Universitaria Pisana) ;
Bennouna, J. (CHU-Nante) ;
Ciardiello, Fortunato ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Aranda Aguilar, Enrique (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Tabernero, J. (Memorial Sloan Kettering Cancer Center) ;
Falcone, A. (Gustave Roussy) ;
Goldberg, R. ;
Argilés, None (Memorial Sloan Kettering Cancer Center) ;
Tabernero, J. (Memorial Sloan Kettering Cancer Center) ;
Mulet, N. (Memorial Sloan Kettering Cancer Center) ;
Limón, M.L. (H. Virgen del Rocío) ;
Valladares, M. (H. Virgen del Rocío) ;
Jiménez, P. (H. Universitario Central de Asturias) ;
Vieitez, J.M. (H. Universitario Central de Asturias) ;
Grávalos, C. (H. 12 de Octubre) ;
García-Alfonso, P. (H. Gregorio Marañón) ;
Santos, C. (ICO. H. Duran i Reynals) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Sastre Valera, Javier (H. Universitario Clínico San Carlos) ;
García Paredes, B. (H. Universitario Clínico San Carlos) ;
Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Aranda Aguilar, Enrique (H. Universitario Reina Sofía) ;
Cano, M.T. (H. Universitario Reina Sofía) ;
Loupakis, F. (IOV (Istituto oncologico Veneto)) ;
Rguez Garrote, M. (H. Ramón y Cajal) ;
Guillén, C. (H. Ramón y Cajal) ;
Rivera, M.F. (H. Marqués de Valdecilla) ;
Safont, J. (H. General Universitario) ;
Hiret, S. (Institut de Cancérologie de l'Ouest) ;
Bennouna, J. (CHU-Nante) ;
Pannier, D. (Centre Oscar Lambret) ;
Malka, D. (Gustave Roussy) ;
Falcone, A. (Gustave Roussy) ;
Cremolini, Chiara (A. O. Universitaria Pisana) ;
Universitat Autònoma de Barcelona
Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). [...]
2022 -  10.1016/j.ejca.2022.09.037
European journal of cancer, Vol. 177 (december 2022) , p. 154-163
|
|
|
2.
|
|
9 p, 351.5 KB |
Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS -mutant metastatic colorectal cancer
/
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Chianese, Chiara (Vall d'Hebron Institut d'Oncologia) ;
Sanz-García, Enrique (Vall d'Hebron Institut d'Oncologia) ;
Martinelli, Erica (Università della Campania 'L. Vanvitelli') ;
Noguerido, Alba (Vall d'Hebron Institut d'Oncologia) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Caratù, Ginevra (Vall d'Hebron Institut d'Oncologia) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Grasselli, Julieta (Vall d'Hebron Institut d'Oncologia) ;
Cardone, Claudia (Università della Campania 'L. Vanvitelli') ;
Esposito Abate, Riziero (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Martini, Giulia ;
Santos Vivas, Cristina (Universitat de Barcelona) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Garcia, Ariadna (Vall d'Hebron Institut d'Oncologia) ;
Mulet, Nuria (Universitat de Barcelona) ;
Maiello, Evaristo (IRCCS Casa Sollievo della Sofferenza) ;
Normanno, Nicola (Istituto Nazionale Tumori 'Fondazione Giovanni Pascale' IRCCS) ;
Jones, Frederick (Sysmex Inostics) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Ciardello, Fortunato (Università della Campania 'L. Vanvitelli') ;
Salazar, Ramon (Universitat de Barcelona) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS -mutant allele fraction (MAF) in plasma in mCRC. [...]
2019 - 10.1002/1878-0261.12547
Molecular Oncology, Vol. 13 (july 2019) , p. 1827-1835
|
|
|
3.
|
|
16 p, 1.5 MB |
Health-related Quality of Life in the Phase III LUME-Colon 1 Study : Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses
/
Lenz, Heinz Joseph (Division of Medical Oncology. USC Norris Comprehensive Cancer Center) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Yoshino, Takayuki (Department of Gastroenterology and Gastrointestinal Oncology. National Cancer Center Hospital East) ;
Lonardi, Sara (Phase 1 Trial Unit and Medical Oncology Unit 1. Istituto Oncologico Veneto IRCCS) ;
Falcone, Alfredo (Department of Oncology. University of Pisa) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sobrero, Alberto (Ospedale Policlinico San Martino IRCCS) ;
Hastedt, Claudia (Boehringer Ingelheim International GmbH) ;
Peil, Barbara (Boehringer Ingelheim Pharma GmbH & Co. KG) ;
Voss, Florian (Boehringer Ingelheim Pharma GmbH & Co. KG) ;
Griebsch, Ingolf (Boehringer Ingelheim International GmbH) ;
Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ;
Universitat Autònoma de Barcelona
Based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) outputs from the LUME-Colon 1 study, we compared and discussed different statistical methods for evaluating health-related quality of life data in oncology clinical trials. [...]
2019 - 10.1016/j.clcc.2019.08.005
Clinical Colorectal Cancer, Vol. 18 Núm. 4 (december 2019) , p. 269-279.e5
|
|
|
4.
|
|
10 p, 1016.0 KB |
Global cancer control : responding to the growing burden, rising costs and inequalities in access
/
Prager, Gerald W. (Medical University of Vienna) ;
Braga, Sofia (Instituto CUF Oncologia) ;
Bystricky, Branislav (Faculty Hospital Trencin) ;
Qvortrup, Camilla (Odense University Hospital (Dinamarca)) ;
Criscitiello, Carmen (Istituto Europeo di Oncologia) ;
Esin, Ece (Ankara Oncology Education and Research Hospital) ;
Sonke, Gabe S. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Frenel, Jean-Sebastian (Institut de Cancerologie de l'Ouest Saint-Herblain) ;
Karamouzis, Michalis (National and Kapodistrian University of Athens) ;
Strijbos, Michiel (AZ KLINA Hospitals) ;
Yazici, Ozan (Ankara Numune Education and Research Hospital) ;
Bossi, Paolo (Fondazione IRCCS Istituto Nazionale Tumori Milano) ;
Banerjee, Susana (Royal Marsden Hospital (Regne Unit)) ;
Troiani, Teresa (Università degli Studi della Campania Luigi Vanvitelli) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Ciardiello, Fortunato (Università degli Studi della Campania Luigi Vanvitelli) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Zielinski, Christoph C. (Medical University Vienna, General Hospital, and Vienna Cancer Center) ;
Casali, Paolo Giovanni (Istituto Nazionale Tumori) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
Jezdic, Svetlana (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Bricalli, Gracemarie (European Society for Medical Oncology) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Ilbawi, André (Disability, Violence and Injury Prevention (NVI), World Health Organization)
The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70. [...]
2018 - 10.1136/esmoopen-2017-000285
ESMO open, Vol. 3 (february 2018)
|
|
|
5.
|
|
10 p, 506.2 KB |
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights
/
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Elez, Elena (Hospital Universitari Vall d'Hebron) ;
Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Matos, Ignacio (Vall d'Hebron Institut d'Oncologia) ;
Sanz García, Enrique (Vall d'Hebron Institut d'Oncologia) ;
Ortiz, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Saurí Nadal, Tamara (Vall d'Hebron Institut d'Oncologia) ;
Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ;
Vilaró, Marta (Vall d'Hebron Institut d'Oncologia) ;
Ruiz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ;
Viaplana, Cristina (Vall d'Hebron Institut d'Oncologia) ;
García Rodríguez, Ariadna (Vall d'Hebron Institut d'Oncologia) ;
Landolfi, Stefania (Universitat Autònoma de Barcelona) ;
Palmer, Héctor G (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia)
Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (s, or the 'mutation dose') of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. [...]
2017 - 10.1002/1878-0261.12099
Molecular Oncology, Vol. 11, Issue 9 (September 2017) , p. 1263-1272
|
|
|
6.
|
|
9 p, 1023.2 KB |
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial
/
Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal (Madrid)) ;
Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Cervantes, Andrés (Universitat de València) ;
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gil Calle, S. (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Mizuguchi, Hirokazu (Taiho Oncology) ;
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
